Global News

[ad_1] A man wearing a mask walks past a Nvidia logo in Taipei, Taiwan. Sopa Images | Lightrocket | Getty Images Chipmaker Nvidia will invest $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm's artificial intelligence models for drug discovery, the companies said Wednesday.  Recursion's stock soared 80% following the announcement. Shares of Nvidia, which have helped fuel stock market gains this year amid hopes about its AI computing chips , rose more than 2%.  Recursion uses AI-powered models to identify and design new therapies, and offers those models to other drugmakers, including Roche and Bayer. Salt Lake City, Utah-based Recursion will use its biological and chemical datasets exceeding 23,000 terabytes to train its AI models on Nvidia's cloud platform. AI models usually require vast amounts of data, typically measured in terabytes, to train them. Nvidia can then potentially license those AI models on BioNeMo, the compan

[ad_1] Investors hoping to capture more upside from artificial intelligence could turn to a sector that's underperformed this year, and maybe not immediately associated with AI: Health care. A handful of large tech names surged in the first half thanks to a mania for all things tied to artificial intelligence. Apple, for example, last week closed with a $3 trillion market capitalization for the first time. Nvidia is up by nearly 200% in 2023. Going forward, some of those gains might spill over to health care, which has underperformed this year. The sector is the third weakest out of 11 in the S & P 500, down about 3% year to date. "A lot of people talk about AI-powered performance and how that's going to impact the tech sector. And I think that's well understood," said Jamie Cox, managing partner for Harris Financial Group. "But what a lot of people fail to appreciate is that artificial intelligence and quantum computing are actually going to have th